The National Institute for Health and Care Excellence (NICE) have started a consultation on Quality Standards for rheumatoid arthritis in patients aged over 16 years.
The consultation will provide the NICE committee with a basis for discussing and prioritising quality improvement areas for development into draft quality statements and measures for public consultation.
This quality standard will cover assessment, diagnosis and management of rheumatoid arthritis in over 16s. It will update and replace the existing NICE quality standard for rheumatoid arthritis in over 16s.
You can follow developments on rheumatoid arthritis by clicking on the Follow Condition button above.
About rheumatoid arthritis (source NICE)
Rheumatoid arthritis is an inflammatory disorder largely affecting synovial joints. It typically affects the small joints of the hands and the feet, and usually affects both sides equally and symmetrically although any synovial joint can be affected.
It presents with swelling, stiffness, pain and progressive joint destruction. There is a rapid loss of muscle around the joint and this along with pain and swelling, leads to loss of function. There may be periods when symptoms become worse (flares) and this can be difficult to predict.
Pain and joint stiffness are usually worse in the morning and after a period of inactivity.
Rheumatoid arthritis can affect the whole-body including eyes, lungs and heart causing for example vasculitis or severe lung fibrosis. It may also be associated with other conditions such as Sjorgren's syndrome (dryness of the eyes and mouth), carpal tunnel syndrome and the presence of rheumatic nodules (hard lumps particularly over surfaces such as the elbow).
© NICE 
Rheumatoid arthritis in over 16s (QS update). In development [GID-QS10136]. Expected publication date: 09 January 2020
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
The information provided by NICE was accurate at the time this article was issued.
NICE consultation information for Quality Standards in rheumatoid arthritis
Reporting of suspected adverse reactions
Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.